LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) (IMUC), a biotechnology company, announced today that the company has exclusively licensed from Cedars-Sinai Medical Center, certain novel peptides (small chains of amino acids) which the Company believes can stimulate the immune system to target cancer stem cells (CSCs) in gliomas, a cancer originating in the brain or spine. These peptides were specifically designed to elicit a T cell response targeting CD133 positive cancer stem cells that have been identified in a number of cancer types, including gliomas, colon cancer and pancreatic cancer.
